Clinical trials: Tics
Trigeminal Neuralgia
Research Study to Test Safety and Effectiveness of Investigational Drug in Patients With Trigeminal Neuralgia
This research study will look at the safety (e.g., the occurrence of side effects) and efficacy (how well the drug works in reducing trigeminal neuralgia attacks) of a drug called lamotrigine in adults with trigeminal neuralgia.
- Trial name
- NCT00203229
- Testing
- lamotrigine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Thomas Jefferson University
Tourette Syndrome in Children, Tourette Syndrome in Adolescence
Ecopipam Tablets to Study Tourette Syndrome in Children and Adolescents - Open Label Extension
This study was an international, multicenter, open-label, long term extension study evaluating the safety of ecopipam tablets for the treatment of children and adolescent subjects with Tourette Syndrome.
- Trial name
- NCT04114539
- Testing
- Ecopipam
- Where
- 65 sites in United States, Canada and 3 more
- Volunteers
- 124 people
- Sponsor
- Emalex Biosciences Inc.
Tourette Syndrome, Tic Disorder, Chronic Motor or Vocal
Open-label MNS for Tourette Syndrome
A recent report (Morera Maiquez et al 2020) described reduced tic severity in people with Tourette syndrome during 1-minute epochs of median nerve stimulation (MNS) at 10 Hz.
- Trial name
- NCT05016765
- Testing
- Active, self-directed electrical stimulation of the median nerve
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Washington University School of Medicine
Tourette Syndrome
An Open-label Study to Determine the Efficacy and Safety of Topiramate in the Treatment of Tourette Syndrome.
Previous studies using topiramate in Tourette subjects have shown that with the use of this medication subjects report that their tics get better.
- Trial name
- NCT00206336
- Testing
- Topiramate (drug)
- Volunteers
- 20 people
- Sponsor
- Baylor College of Medicine
Tourette Syndrome
Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette Syndrome
This is an open-label, rollover study to collect long-term safety, tolerability, and investigator- and participant-reported pharmacodynamic (PD) data after chronic administration of NBI-98854 in pediatric participants with…
- Trial name
- NCT03732534
- Testing
- NBI-98854
- Where
- 10 sites in United States, Puerto Rico
- Volunteers
- 6 people
- Sponsor
- Neurocrine Biosciences
Tourette's Disorder
Proof-of-Concept Safety Study of CPP-109 (Vigabatrin) for Treatment Refractory Tourette's Disorder
The purpose of this study is to determine if vigabatrin, an unusual anti-seizure medication, will diminish the Tourette Disorder outbursts in young adults whose symptoms have persisted into adulthood and have not responded to…
- Trial name
- NCT01585207
- Testing
- vigabatrin
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Barbara J. Coffey
Tourette Syndrome
Developing New Treatments for Tourette Syndrome: Therapeutic Trials With Modulators of Glutamatergic Neurotransmission
A joint NIH -Tourette Syndrome Association Conference has emphasized the critical need for the testing and development of new pharmacotherapy for tic suppression in Tourette syndrome (TS).
- Trial name
- NCT01018056
- Testing
- D-serine, Riluzole
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Johns Hopkins University
Tourette Syndrome
Tourette Syndrome Deep Brain Stimulation
The purpose of this study is to evaluate the effectiveness and safety of deep brain stimulation (DBS) as a possible new treatment for Tourette Syndrome (TS).
- Trial name
- NCT02056873
- Testing
- Continuous DBS, Responsive Brain Stimulation (RBS Setting)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Florida
Tourette Syndrome
Open-Label Safety and Tolerability Study of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
This is a Phase 2b, multicenter, open-label study to evaluate the safety and tolerability of optimized doses of NBI-98854 administered once daily for 24 weeks in pediatric subjects with Tourette Syndrome.
- Trial name
- NCT03444038
- Testing
- Valbenazine
- Where
- 37 sites in United States, Puerto Rico
- Volunteers
- 85 people
- Sponsor
- Neurocrine Biosciences
Tourette's Syndrome
Ecopipam Treatment of Tourette's Syndrome in Subjects 7-17 Years
Tourette's Syndrome is a neurological disease characterized by motor and vocal tics. It has been hypothesized that abnormal interactions of dopamine with its receptors may cause the tics.
- Trial name
- NCT02102698
- Testing
- Ecopipam
- Where
- 11 sites in United States
- Volunteers
- 40 people
- Sponsor
- Emalex Biosciences Inc.
Tourette's Syndrome, Tic Disorders
Open Label Trial of Aripiprazole in Children and Adolescents With Tourette's Disorder
The purpose of this study is to determine if Abilify will reduce tics (repetitive, uncontrollable movements or vocalizations) in children and adolescents ages 7-18 with Tourette's Disorder (TD) or a chronic motor tic disorder…
- Trial name
- NCT00241176
- Testing
- Aripiprazole
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- NYU Langone Health
Tick-Borne Encephalitis, Encephalitis, Tick-Borne
Vaccine Study for Tick-Borne Encephalitis Virus (TBEV)
This was an open label trial of a non-US licensed vaccine for tick-borne encephalitis. The vaccine was licensed by Baxter, and now following an acquisition by Pfizer Inc in Vienna, Austria since 2001, and has an extensive safety…
- Conditions
- Tick-Borne Encephalitis, Encephalitis, Tick-Borne, Tick-Borne Disease, Glycoprotein E, Flavivirus
- Trial name
- TBEV (NCT01031537)
- Testing
- FSME-IMMUN 0.5ml Baxter
- Where
- 2 sites in United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Tourette Syndrome
Safety and Efficacy Study of NBI-98854 in Children and Adolescents With Tourette Syndrome
Phase 2, double-blind, placebo-controlled study to assess the safety and efficacy of NBI-98854 administered once daily (qd) for a total of 6 weeks of treatment.
- Trial name
- NCT02679079
- Testing
- NBI-98854
- Where
- 44 sites in United States
- Volunteers
- 98 people
- Sponsor
- Neurocrine Biosciences
Tourette's Disorder (TD)
Trial to Evaluate the Long-term Efficacy of Oral Aripiprazole in the Treatment of Pediatric Participants With Tourette's Disorder
To evaluate the long-term efficacy of oral aripiprazole in pediatric participants for the treatment of Tourette's Disorder (TD).
- Trial name
- NCT03661983
- Testing
- Aripiprazole
- Where
- 42 sites in United States, Canada and 1 more
- Volunteers
- 36 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Tourette Syndrome
Pramipexole Pilot Phase II Study in Children and Adolescents With Tourette Disorder According to DSM-IV Criteria
A randomized, double-blind, placebo-controlled, flexible dose study to evaluate efficacy and safety of Pramipexole versus placebo for 6 weeks in children (age 6-17) diagnosed with Tourette Disorder according to DSM IV criteria.
- Trial name
- NCT00558467
- Testing
- pramipexole immediate release (IR)
- Where
- 16 sites in United States, Germany
- Volunteers
- 63 people
- Sponsor
- Boehringer Ingelheim
Tourette Syndrome
Open-label Extension Study of Pramipexole in the Treatment of Children and Adolescents With Tourette Syndrome
The primary objective of this open-label, flexible dose study is to assess the safety and efficacy of pramipexole over a 24-week period in children and adolescents (age 6-17 years inclusive) diagnosed with Tourette Syndrome…
- Trial name
- NCT00681863
- Testing
- pramipexole 0.125 mg BID, pramipexole 0.0625 mg QD, pramipexole 0.125 mg TID
- Where
- 14 sites in United States, Germany
- Volunteers
- 45 people
- Sponsor
- Boehringer Ingelheim
Tourette Syndrome
Alternatives for Reducing Tics in Tourette Syndrome (TS): A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Tourette Syndrome in Children and Adolescents
This is a study to evaluate the efficacy and safety of deutetrabenazine (TEV-50717) tablets for the reduction of motor and phonic tics associated with TS in children and adolescents 6 through 16 years of age.
- Trial name
- ARTISTS1 (NCT03452943)
- Testing
- TEV-50717
- Where
- 42 sites in United States, Canada and 4 more
- Volunteers
- 119 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Tourette Syndrome
A Study to Test if TEV-50717 is Effective in Relieving Tics Associated With Tourette Syndrome (TS)
Standard placebo-controlled, double-blind study design (TEV-50717 [low dose and high dose] vs. placebo in a 1:1:1 ratio) was chosen to determine whether study drug treatment results in a statistically significant effect on the…
- Trial name
- ARTISTS2 (NCT03571256)
- Testing
- TEV-50717
- Where
- 56 sites in United States, Argentina and 8 more
- Volunteers
- 158 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Tic Disorders, Tics
Transcranial Magnetic Stimulation to Augment Behavior Therapy for Tics
The study will examine whether combining Comprehensive Behavioral Intervention for Tics (CBIT) with inhibition of the supplementary motor area (SMA) using transcranial magnetic stimulation (TMS) normalizes activity in the…
- Conditions
- Tic Disorders, Tics, Tic, Motor, Tic Disorder, Childhood
- Trial name
- NCT04578912
- Testing
- Comprehensive Behavioral Intervention for Tics (CBIT), Repetitive Transcranial Magnetic Stimulation (rTMS), Continuous Theta Burst Stimulation (cTBS)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Minnesota
Tourette's Disorder
ABF Tourette's Disorder Post Marketing Surveillance Study
This is a Post-Marketing Surveillance study of Abilify® tablets in accordance with Korean regulations on New Drug Re-examination (i.e. New Drug Re-examination Standards: KFDA Notification No. 2010-94 dated 27 December 2010).
- Trial name
- NCT01795105
- Where
- 4 sites in South Korea
- Volunteers
- 692 people
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.